Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Affimed Therapeutics (AFMD)
:AFMD
Holding AFMD?
Track your performance easily
AFMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $8.95
Previous CloseN/A
Volume135.33K
Average Volume (3M)498.61K
Market Cap
$16.45M
Enterprise Value$41.58M
Total Cash (Recent Filing)$44.89M
Total Debt (Recent Filing)$3.62M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 27, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding15,227,463
10 Day Avg. Volume267,478
30 Day Avg. Volume498,613
Standard Deviation0.23
R-Squared0.25
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.94
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap2.53
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$7.67Price Target Upside610.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Affimed News
PremiumCompany Announcements
Affimed’s Promising Clinical Update on NSCLC Treatment
Bulls Say, Bears Say
Bulls Say
Investor InterestUpdated outcomes for AFM28 and acimtamig could garner investor re-attention in the stock.
Partnership OpportunitiesAffimed’s three active molecules should be of interest to pharma, and a partnership with non-dilutive financing would provide significant support for the stock.
Positive Clinical DataAFMD highlighted positive data from the LuminICE-203 study in cHL, showing significantly higher ORR compared to the only currently available option.
Bears Say
Clinical And Safety ConcernsCRS was reported in 27% of patients, with one case being Grade 3, which is a safety concern.
Financial PerformanceThe initiation of the PTCL cohort in LuminICE-203 is contingent upon securing additional capital, highlighting financial constraints.
Funding And InvestmentThere is a 1-1.5 year delay and uncertainty in source of funding for the higher dose strategy, raising concerns about financial sustainability and growth.
---
Ownership Overview
―
Insiders
1.59% Mutual Funds
10.25% Other Institutional Investors
88.16% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AFMD FAQ
What was Affimed Therapeutics’s price range in the past 12 months?
Affimed Therapeutics lowest stock price was $1.03 and its highest was $8.95 in the past 12 months.
What is Affimed Therapeutics’s market cap?
Affimed Therapeutics’s market cap is $16.45M.
When is Affimed Therapeutics’s upcoming earnings report date?
Affimed Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 67 days.
How were Affimed Therapeutics’s earnings last quarter?
Affimed Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.969 earnings per share for the quarter, missing the consensus estimate of -$0.951 by -$0.018.
Is Affimed Therapeutics overvalued?
According to Wall Street analysts Affimed Therapeutics’s price is currently Undervalued.
Does Affimed Therapeutics pay dividends?
Affimed Therapeutics does not currently pay dividends.
What is Affimed Therapeutics’s EPS estimate?
Affimed Therapeutics’s EPS estimate is -0.76.
How many shares outstanding does Affimed Therapeutics have?
Affimed Therapeutics has 15,227,463 shares outstanding.
What happened to Affimed Therapeutics’s price movement after its last earnings report?
Affimed Therapeutics reported an EPS of -$0.969 in its last earnings report, missing expectations of -$0.951. Following the earnings report the stock price went down -2.667%.
Which hedge fund is a major shareholder of Affimed Therapeutics?
Among the largest hedge funds holding Affimed Therapeutics’s share is Baker Bros Advisors LP. It holds Affimed Therapeutics’s shares valued at 0.
---
Company Description
Affimed Therapeutics
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
---
AFMD Company Deck
---
AFMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly with AFM24 and AFM28, and a strategic focus on partnerships and financial health. However, there were notable challenges, including a decline in revenue and reduced cash reserves. Despite these challenges, the company's efforts to improve its financial position and strategic focus are promising.Read More>---
AFMD Stock 12 Month Forecast
Average Price Target
$7.67
▲(610.19% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Immutep
―
Karyopharm Therapeutics
―
Kura Oncology
―
Xencor
―
Zymeworks
―
Best Analysts Covering AFMD
1 Year
1 Year Success Rate
1/11 ratings generated profit
1 Year Average Return
-50.61%
assigned a buy rating last month
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -50.61% per trade.
---